12:00 AM
 | 
Mar 26, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Votrient pazopanib regulatory update

FDA's Oncologic Drugs Advisory Committee voted 11-2 that the benefit-risk profile of GlaxoSmithKline's Votrient pazopanib supports approval to treat advanced soft tissue sarcoma. Committee members...

Read the full 105 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >